Share on LinkedInShare on LinkedIn

ARTICLE · 19 SEPTEMBER 2025

Combination Therapies In Belgium: How To Collaborate Without Breaching Competition Law

ALTIUS
ALTIUS
Contributor
ALTIUS

ALTIUS

ALTIUS is one of the largest Belgian independent law firms. Established in Brussels and...

View firm profile
Explore more from ALTIUS

As the landscape of modern medicine evolves, combination therapies—those that use two or more distinct medicines, often from different companies...

BelgiumAntitrust/Competition Law

As the landscape of modern medicine evolves, combination therapies—those that use two or more distinct medicines, often from different companies—are becoming increasingly vital, especially in treating complex diseases like cancer. These therapies promise improved clinical outcomes through synergistic mechanisms of action. However, the reimbursement process for such therapies presents significant regulatory and legal challenges, particularly in the area of information sharing between pharmaceutical companies. Recognising this issue, the Belgian Competition Authority (the "BCA") has issued on 10 September 2025 a communication clarifying how companies can cooperate without breaching competition law.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from